Abstract: A method of preparing a salt product comprises the steps of: (i) providing a mixture which comprises salt dissolved in a solvent, said mixture further containing an organic material that is solid under ambient temperature conditions; and (ii) atomising said mixture and evaporating said solvent to produce a salt product comprised of particles of salt incorporating said organic material. The organic material may be a polymer such as a carbohydrate (e.g. maltodextrin or Gum Arabic). Novel salt products are disclosed which comprise hollow particles having a shell formed for individual crystallites of salt. The salt product is useful as a seasoning for food and may be used in lower amounts than conventional salt to provide the same taste. Particular advantages are obtained in the baking of bread.

Abstract: The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness with compared to rapid disintegrating tablets of the prior art. The above objective is solved by a composition for rapid disintegrating tablets in oral cavity, wherein components (a) to (c) are contained in such manner that (a) saccharides consisting of a combination of mannitol and xylitol is 40 to 90 parts by weight; (b) the inorganic excipient is 1 to 30 parts by weight; and (c) the disintegrating agent is 5 to 40 parts by weight, provided that the total amount of (a), (b) and (c) is 100 parts by weight.

Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.

Abstract: A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coated with the sugar coating layer, and a middle layer that includes a film component and a sugar coating component and is provided between the film layer and the sugar coating layer, wherein within the middle layer, the concentration of the sugar coating component at the interface between the middle layer and the sugar coating layer is higher than the concentration of the sugar coating component at the interface between the middle layer and the film layer.

Abstract: Catheter injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions are have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.

Abstract: The embodiments set forth herein provide biocompatible self-setting compositions suitable for use in tissue augmentation applications. The biocompatible self-setting compositions described herein exhibit advantageous theological properties and may be applied to a site in the body of a patient by injecting the composition through a 20-30 gauge needle. Once applied to a site in the body, the composition sets to a slow resorbing or substantially non-resorbing matrix. Advantageously, exposure of the composition material to body heat at its site of use enhances setting of the composition.

Abstract: An erodible prosthesis comprising alternate rates of erosion is disclosed, wherein said alternate rates of erosion can be selectively initiated. Some embodiments according to the invention may comprise an agent for initiating an alternative rate of erosion, such as, for example, a sensitizer, dissolution inhibitor, photo-acid generator, biochemically active additive, thermally activated catalyst, light activated catalyst, electromagnetic radiation activated catalyst, hydration activated catalyst, pH activated catalyst, low melting agent, and/or enzyme activated catalyst. One or more of the foregoing agents may be dispersed within one or more layers.

Abstract: A firm but pliable medical device for use as a bone graft substitute or bone graft extender retains its shape without the requirement of a containment device, such as a syringe. Because the device is solid, it is easy to locate or position in-vivo and, in the moist environment of the body, it will hold its shape well, for an extended time. Because the lyophilized pliable medical device is porous, it adsorbs blood and other beneficial cells containing body fluids, such as bone marrow, contributing to its superior bone repair efficacy in comparison to an analogous putty that has not been lyophilized. In addition these lyophilized pliable medical devices are easier to terminally steam sterilize than the analogous putty because there is no moisture present to boil and “blow-out” of the containment device (syringe). The glycerin that is present in the formulation lends pliability but has a low vapor pressure.

Abstract: Effective treatments of pain and/or inflammation are provided that utilize a reversible phase transition material of a drug depot. When heat, cold or another suitable form of energy, e.g., ultrasound energy is applied to the reversible phase transition material, the release of an analgesic and/or anti-inflammatory agent from a drug depot is increased.

Abstract: The present invention refers to pharmaceutical compositions based on ketorolac or one of its salts pharmaceutically acceptable, as well as the use of ketorolac or one of its salts acceptable from pharmaceutical viewpoint, for preparation of a pharmaceutical composition (tablets) for sublingual administration, with the purpose of accelerating the pharmacological response to ketorolac, without making use of the injectable via. On the other hand, a pharmaceutical composition is described encompassing, as one of its active principles, ketorolac or one of its salts acceptable from pharmaceutical viewpoint, representing from 10 to 15% by weight, in relation to the total weight of the compound and as the essential excipient, a ternary mixture of lactose/sorbitol/cellulose, eventually in a mixture with other excipients acceptable from pharmaceutical viewpoint.

Abstract: The invention concerns a process for the production of a tableting excipient with the following process steps: At least two of the following components are made available: A filler/binding agent; A lubricant; A flow regulating agent; A disintegrant; The available components are mixed together.

Abstract: An ophthalmic composition comprising therapeutically effective amount of a beta-blocker and a polymeric vehicle consisting essentially of a water soluble cellulose derivative and polyvinylpyrrolidone; wherein the composition is a clear aqueous solution with a viscosity id 20 cps to 60 cps.

Abstract: The disclosure relates to a biomaterial that comprises an aqueous phase, polymer network, a second polymer included in said disclosure invention more particularly relates to a biomaterial including an aqueous phase and a first polymer network made of a first proteic or saccharidic polymer or a mixture of first proteic and saccharidic polymers, wherein the first polymer network and the aqueous phase define a first gel (A), the biomaterial including: a second proteic or saccharidic polymer or a mixture of the second proteic and saccharidic polymers, either in solution in the aqueous phase of the gel (A) or in the form of a gel (B), and a first enzyme for degrading said second polymer or second polymer network. The disclosure also relates to a method for making biomaterials, and to the uses of the biomaterial particularly for releasing active substances, and to a device for the controlled release of active substances that include the biomaterial.

Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.

Abstract: A controlled release melatonin tablet having a slow release nucleus of melatonin, hydroxypropyl methylcellulose, a lubricant, a volume excipient and a glidant, wherein 95% of the melatonin is released within 5 hours in an oscillating tray containing gastric/intestinal juice at 37° C. and a fast release cortex coating on said nucleus of melatonin, hydroxypropyl methylcellulose and a volume excipient, wherein at least 95% of the melatonin is released within 10 minutes in an oscillating tray containing gastric/intestinal juice at 37° C.

Abstract: The invention relates to improved isomalt-containing tablets and to methods for the production thereof.

Abstract: Non-crosslinked derivatives of oligo/polysaccharides of formula I, wherein: X is OH, OM, NH—R1, O—R1; M is an alkaline or alkaline-earth metal, transition metal, or cation containing a quaternary nitrogen atom; Y is H or R2; R1: the residue of an oligo/polysaccharide; R2: the residue of a C1-C4 linear chain aliphatic carboxylic acid or citric acid; provided that at least one X is NH—R1 or O—R1, while the other two X are present in acid (OH) or salified form (OM).

Abstract: The present invention is directed to coprocessed excipient particles comprising a cellulosic material such as microcrystalline cellulose in intimate association with silicon dioxide, a disintegrant and a polyol, sugar or a polyol/sugar blend. The excipient particles display good processing and are useful in prepared compressed solid dosage forms that exhibit rapid disintegration (less than about 60 seconds) when placed on the tongue or when tested according to USP disintegration testing, while still providing acceptable mouth feel.

Abstract: The invention provides an orally disintegrating tablet containing (a) one or more saccharides or sugar alcohols selected from the group consisting of mannitol, lactose, xylitol, sucrose, erythritol and glucose and (b) low substituted hydroxypropylcellulose and substantially free of a starch disintegrant, which tablet is produced by steps of granulating a composition containing the above-mentioned components (a) and (b) by an agitation granulation method, and compression-molding the obtained granulation product. The invention also provides a method of producing an orally disintegrating tablet substantially free of a starch disintegrant, including steps of granulating a composition containing the above-mentioned components by an agitation granulation method, and compression-molding the obtained granulation product.

Abstract: An excipient base for a chewable tablet comprising xylitol, sucralose and microcrystalline cellulose. The excipient base provides for an improved taste, stabilization, and mouthfeel qualities for the chewable tablet, as well as a greater likelihood for dosage compliance and use. The excipient base also enables the tablet to be directly compressible, free flowing and non-tacky, thus avoiding wet granulation techniques that can degrade the product and add to the cost of the manufacturing process. The excipient base also allows for the production of a chewable tablet that is suitable for administration to persons and animals having diabetes or hypoglycemia, and does not promote tooth decay or dental caries.

Abstract: Personal care dissolvable films comprising a water soluble film forming agent, cosmetically acceptable plasticizer, and detackifying agent are described, along with methods of using the same.

Abstract: The invention relates to a biocompatible metastable intermediate material for controlling the mobility of at least one biologically active substance. An example of the invention is a hydrogel formed by cross-linked sodium hyaluronate treated with an oxidizing agent so as to open sugar rings and form aldehyde groups. The gel according to the invention is sterilized, e.g. by autoclaving.

Abstract: The present invention relates to a composition for cosmetic raw material containing cellulose dyed with a natural coloring matter having improved photostability, and a visual carrier system comprising the same. In the composition for cosmetic raw material and the visual carrier system comprising the same according to the present invention, by using no iron oxide chemical coloring matter and applying a typical and natural dyeing method of cloths to the microcrystalline cellulose that is the cosmetic raw material, photostability that is a problem of the natural coloring matter in the related art is largely improved.

Abstract: The present disclosure provides polymer compounds binding with lipoamide produced by the reaction of the primary amine group of lipoamide with the carboxy group of polysaccharide compounds such as chondroitin sulfates, carboxymethyl celluloses, or hyaluronic acids; functional compounds such as peptides, proteins, growth factors; or drugs; or biocompatible polymers such as poly(ethylene oxide), poly(vinyl alcohol), or poly(vinyl pyrrolidone). The present disclosure also provides their synthesis methods, products of hydrogels and films using the same as and methods for manufacturing the products.

Abstract: The present invention provides a tablet coating composition including a cellulose polymer, a plasticiser, a sweetener, and a powdered flavour composition. The powdered flavour composition includes a flavourant associated with a solid carrier. The present invention also provides a pharmaceutical tablet including a core containing an active agent and a coating formed from the tablet coating composition.

Abstract: A drug-eluting device comprising a drug-eluting matrix containing at least one elutable drug, a method of manufacturing a preformed drug-eluting device, and an implant kit comprising the same.

Abstract: A water-soluble electrospun sheet, containing a water-soluble base material made of at least one material selected from a group consisting of: high-molecular proteins and decomposition products thereof; cellulose-based polymers; plant-based polymers and decomposition products thereof; vinyl-based polymers; acrylic-based polymers; and water-soluble polysaccharides; is provided. In addition to the water-soluble base material, the sheet may further contain at least one functional component selected from among: emulsifying components; stabilizing components; antimicrobial components; humectant components; skin-whitening components; anti-ultraviolet components; astringent components; keratin-softening components; anti-inflammatory components; and coloring components.

Abstract: A drug-eluting implant cover fabricated from a drug-eluting biocompatible matrix containing at least one elutable drug, a drug-eluting implant cover kit containing at least one drug-eluting implant cover, and a method of manufacturing the same.

Abstract: A contact lens (4) comprises a solid component capable of imparting shape and structure to said lens, and a liquid component, at least partially contained in the solid component, capable of favouring the compatibility between said lens and the eye of a user of said lens, wherein the liquid component comprises a solution capable of being used as a lachrymal substitute.

Abstract: The present invention relates to a novel ingestible film composition. More specifically, the invention is directed to a water-based, enzymatically-digested carboxymethylcellulose (CMC-Enz) film composition that is suitable for delivering pharmaceutical drugs, vitamins, natural products and other products to humans and animals. The invention further includes a method for manufacturing the novel composition. Advantageously, the film composition can accommodate an active ingredient in a quantity of up to approximately 60% of the overall weight of the final film.

Abstract: The deposition of a benefit agent on a substrate after treatment of the substrate with a personal care composition which has a viscosity of at least 50 mPa·s at 25° C. and comprises the benefit agent and a low molecular weight surfactant is improved when a water-soluble polymer is used as a substitute for at least a portion of the low molecular weight surfactant. The headspace concentration of a fragrance provided by such personal care composition is also increased.

Abstract: A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers.

Abstract: A solid dosage form is provided which includes an active agent and silicified microcrystalline cellulose, the dosage form formed by a) combining a wetted active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and b) incorporating the agglomerated particles into the solid dosage form. In certain preferred embodiments, step b comprises combining said silicified microcrystalline cellulose, said active agent, and colloidal silicon dioxide in a dryer. Preferably, the dryer is a spray dryer, and, in certain embodiments, the active agent may be an herbal extract.

Abstract: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.

Abstract: The present composition is capable of forming a particle film and comprises: (a) less than 99.65% by weight of at least one particle; (b) at least one volumizing agent selected from the group consisting of: (i) cellulose selected from the group consisting of ethyl hydroxy ethyl cellulose, hydroxy ethyl cellulose, hydroxy propyl cellulose, hydroxy ethyl methyl cellulose, hydroxy propyl methyl cellulose, methyl cellulose, ethyl cellulose, and ethyl methyl cellulose and present in an amount greater than 0.35% by weight; and (ii) non-cellulosic component or cellulose other than said cellulose (i) present in an amount of at least 0.05% by weight; and optionally (c) at least one spreader. The composition may be used to form agricultural films.

Abstract: The invention provides a multi-compartmented container suitable for the delivery of pharmaceuticals, medicines, vitamins, and the like.

Abstract: A powder•particle dosage form obtained by granulating an excipient and/or a disintegrating agent with a liquid in which a bitter taste masking base is dissolved and/or suspended, and a drug having solubility in water (20° C.) of not higher than 1 g/mL is dissolved or suspended, or a tablet obtained by compressing the powder•particle dosage form could mask bitter taste of a drug.

Abstract: Personal care dissolvable films comprising a water soluble film forming agent, cosmetically acceptable plasticizer, and a thickener are described, along with methods of using the same.

Abstract: The present invention provides an aqueous composition obtained by dissolving, in water, hydroxyethyl cellulose, methyl cellulose and/or Hypromelose and the invention also provides a medicament comprising the aqueous composition and a drug incorporated therein. The viscosity of the composition of the present invention is abruptly increased when heated at a temperature near the body temperature, but it is rapidly reduced when applying weak force thereto, for instance, by lightly shaking the same. When the medicament obtained by incorporating a drug into the composition of the present invention is administered to a living body, the composition of the present invention can be thickened without delay at the administered site and thus stay at that site over a long period of time and this in turn leads to a considerable increase of the BA of the drug.

Abstract: A physical blend of inverse thermal gelling and shear-thinning, thixotropic polymers that has a lower gelation temperature than the thermal gelling polymer alone is provided. The blend results in an injectable hydrogel that does not flow freely at room temperature, but is injectable due to its shear-thinning properties. The thermal-gelling properties of the polymer promote a more mechanically stable gel at body temperature than at room temperature. The polymer matrix gel has inherent therapeutic benefit and can also be used as a drug delivery vehicle for localized release of therapeutic agents.

Abstract: A polysaccharide-based solid material including, in its mass, at least one active agent having bactericidal, fungal, insecticidal and/or flame-retardant properties, and at least one complexing agent and/or at least one polymeric matrix having a complexing agent. The active agent includes at least one compound selected from the group including boron, silica, aluminum, phosphorus, iodine, derivatives thereof, aluminosilicate derivatives, and mixtures thereof. The solid material is characterized by an improved stability and by reduced environmental impact, and makes it possible to prepare materials based on wood particles and woods having a particular resistance against environmental attacks such as moisture.

Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising: a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties; and a physiologically active substance.

Abstract: An oil-in-water type emulsion contains a very small quantity of surfactant, so that the emulsion is stable, well tolerated and non-irritating. The emulsion is used as the base for compositions intended to be applied to sensitive tissues of the body of a human or animal, in particular in ophthalmic, dermatological and dermocosmetic compositions.

Abstract: A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.

Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficultly soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.

Abstract: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.

Abstract: A granular material which has a mean particle diameter of 150 to 800 micrometers; and an unsettled bulk density of 0.1 to 0.35 g/cm3 and/or a compactibility which results in a compact with a tensile strength of at least 1.7 MPa when the granular material is subjected to a compaction pressure of 266 MPa; and wherein the main component of the granular material is a cellulose derivative or an alkylene oxide homo- or copolymer or a blend thereof is useful for preparing dosage forms with a controlled release profile.

Abstract: Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously.

Abstract: Compositions for embolization are disclosed herein. The compositions disclosed can have a matrix-forming component, a solid-aggregate material, and a rheology modifying agent, wherein the matrix-forming component includes at least alkyl cyanoacrylate monomers, a stabilizer, and a plasticizer, and the solid-aggregate material includes at least a radiopacifier. The composition and a method of administering the composition are useful for treating vasculature abnormalities, particularly when the composition solidifies upon contact with an ionic environment, such as blood.

Abstract: A viscoelastic composition for injection into a human eye comprised of about 2.0 to 2.5 percent of hydroxypropyl methylcellulose dissolved in a physiological salt solution, the composition, the composition having a viscosity from about 15,000 to about 40,000 centipoise and the hydroxypropyl methylcellulose having a molecular weight from about 220,000 to less than about 420,000 Daltons, the composition being free of debris or gels greater than 0.5 ?m. Also described is a process for preparing the clean, high molecular weight hydroxy propylmethyl cellulose composition.